PW Medtech Group (HKSE:01358) Margin of Safety % (DCF Earnings Based): N/A (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01358 PW Medtech Group Ltd HKSE:01358
77 GF Score
Price HK$0.91
GF Value HK$1.32
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is PW Medtech Group Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

PW Medtech Group's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

HKSE:01358 vs ISRG, BDX, MDLN: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Instruments & Supplies subindustry, PW Medtech Group's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PW Medtech Group Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where PW Medtech Group's Margin of Safety % (DCF Earnings Based) falls into.


HKSE:01358
77GF Score
PW Medtech Group Ltd HKSE:01358
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PW Medtech Group (HKSE:01358) Overvalued in 2026?

Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued. The current stock price of HK$0.91 is trading 31.4% below its estimated GF Value™ of HK$1.32. GuruFocus considers PW Medtech Group to be Significantly Undervalued.

Key valuation signals for HKSE:01358:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: HK$1.32 vs. price of HK$0.91 (31.4% below fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the HKSE:01358 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PW Medtech Group Business Description

Other Exchanges PWE:Germany
Address No. 23 Panlong West Road, Building 1, Pinggu District, Beijing, CHN, 101204
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
77GF Score

Get the complete analysis for HKSE:01358

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.91
Price
HK$1.32
GF Value